Cargando…
Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS(G12D) Mutation
[Image: see text] Effective oral therapies are urgently required to treat KRAS(G12D) mutant cancers. Therefore, synthesis and screening were performed for 38 prodrugs of MRTX1133 to identify an oral prodrug of MRTX1133, a KRAS(G12D) mutant protein-specific inhibitor. In vitro and in vivo evaluations...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2023
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948199/ https://www.ncbi.nlm.nih.gov/pubmed/36844555 http://dx.doi.org/10.1021/acsomega.3c00329 |